Moleculin Biotech's second quarter 2026 loss was $1.40 per share with cash runway into early 2027

Moleculin Biotech reported a net loss of $7.6 million and no revenue for the second quarter of 2026, as the company remains focused on its clinical pipeline. The company’s liquidity was bolstered by a $9.3 million capital raise following the quarter's end, which management expects will fund operations into the first quarter of 2027. Clinical efforts continue to center on the Phase 2/3 MIRACLE trial, which recently yielded positive interim efficacy data in patients with relapsed or refractory acute myeloid leukemia.

Key Highlights

• Interim data from the first 45 MIRACLE trial patients showed complete remission rates of 43% and 36% in the Annamycin arms, more than triple the 12% rate observed in the control group.
• Research and development expenses rose to $5.5 million, up from $3.6 million in the prior year quarter, primarily due to an additional $1.1 million in MIRACLE trial costs.
• The company maintains a cardiac-safe profile for Annamycin, reporting no detectable cardiotoxicity in the MIRACLE trial despite cumulative exposures exceeding conventional anthracycline limits.